1. Arbyn M, Castellsague X, de Sanjose S et al (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675–2686
2. Baldwin PJ, van der Burg SH, Boswell CM et al (2003) Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9:5205–5213
3. Bodily J, Laimins LA (2010) Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 19:33–39
4. Bontkes HJ, de Gruijl TD, Walboomers JM et al (1997) Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 76:1353–1360
5. Borysiewicz K, Fiander A, Nimako M et al (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523–1527